Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CFZ533 in primary Sjögren's syndrome
2013-004808-19Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in primary Sjögren's syndrome comparing CFZ533 with Placebo (2 arms). Primary endpoint: Adverse event monitoring. Started Mar 2014; status: completed.
02
Drugs
iscalimab
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on 2013-004808-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004808-19.